Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-76.66	-54.19	-43.48	-84.94	-84.23	-76.28
Depreciation & Amortization	3.03	3.2	4.58	4.46	5.6	8.68
Share-Based Compensation	5.54	4.77	3.05	8.92	8.19	8.24
Other Operating Activities	28.28	9.21	-11.42	5.89	35.43	-3.45
Operating Cash Flow	-39.8	-37.01	-43.48	-65.67	-35.02	-62.82
Capital Expenditures	-0.63	-0.13	1.6	-4.15	-1.34	-6.31
Change in Investments	-9.19	0.34	-25.57	70.21	-82.38	66.48
Other Investing Activities	-	-	-	-	-	-0.2
Investing Cash Flow	-9.82	0.21	-23.96	66.06	-83.71	59.98
Share Issuance / Repurchase	43.61	37.21	46.96	24.86	0.18	113.9
Debt Issued / Paid	18.89	-0.15	0	0	1.76	0
Other Financing Activities	-	-	-3.78	-	-	-
Financing Cash Flow	62.5	37.06	43.17	24.86	1.94	113.9
Net Cash Flow	12.88	0.26	-24.27	25.26	-116.8	111.06
Free Cash Flow	-40.44	-37.14	-41.88	-69.82	-36.36	-69.13
Free Cash Flow Margin	-1155.34%	-1061.03%	-2961.74%	-2327.20%	-363.55%	-
Free Cash Flow Per Share	-1.48	-1.74	-5.33	-17.73	-9.81	-34.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).